Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Context Therapeutics: Identification of CTIM-76, a CLDN6xCD3 bi-specific antibody

Context Therapeutics: Identification of CTIM-76, a CLDN6xCD3 bi-specific antibody

Context Therapeutics — 4 videos in collection

More on this equity

Context Therapeutics (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company committed to advancing medicines for female cancers. The company’s pipeline includes small molecule and bi-specific antibody drug candidates that target cancer signaling pathways. ONA-XR (onapristone extended release), a novel, first-in-class potent and selective progesterone receptor antagonist, is currently in three Phase II clinical trials and one Phase Ib/II clinical trial in hormone-driven breast, ovarian and endometrial cancers. Context is also developing CTIM-76, a selective CLDN6xCD3 bi-specific antibody for CLDN6 positive tumors, currently in pre-clinical development.

In this webinar, the Context Therapeutics management team, along with two experts in the field, discuss the company’s CLDN6 program and the recently announced selection of CTIM-76, a T cell-engaging bi-specific antibody, as its lead clinical development candidate.

< Previous
Next >

You may also be interested in these:

Healthcare

Context Therapeutics webinar: Claudin 6 x CD3 bispecific antibody data update

Healthcare

Key opinion leader webinar: Context Therapeutics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free